• Savino Sciascia, Eva Talavera-Garcia, Dario Roccatello, Simone Baldovino, Elisa Mengatti, and Maria Jose Cuadrado.
• Centro di Ricerche di Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare (CMID), Department of Clinical and Biological Sciences, Università di Torino, Italy; Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, UK.
• Int. Immunopharmacol. 2015 Aug 1; 27 (2): 189-93.

AbstractSystemic lupus erythematosus (SLE) is a chronic autoimmune condition with unpredictable course, intermingled with flares and periods of remission. Although the prognosis of the disease has improved in the past decades, current therapies are still associated with treatment-related complications. Recently, there has been major progress in the understanding of the pathogenesis of SLE, paving the way for the development of new biological agents, potentially revolutionizing the treatment of SLE. This review summarizes available data on novel biological therapies for SLE, focusing on recent results from clinical trials. As a result of treatment strategies based upon an individualized therapeutic approach, it is hoped that the clinical view of SLE will change from a severe autoimmune disease to a condition in which significant damage, mortality and treatment related complications can be prevented in the majority of SLE patients. Copyright © 2015. Published by Elsevier B.V.

11 keywords...

hide…